Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of 2024 ...

Based in Irvine, device maker Axonics Inc. reported fourth-quarter revenue climbed 61% to $85.6 million to $86 million, topping the $78.1 million expected by analysts. “This quarter’s record revenue ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...

Medical device maker Boston Scientific said on Monday it had agreed to buy Axonics for $3.7 billion, gaining access to devices used to improve bladder function. The deal marks Boston Scientific's ...

Irvine-based medical device maker Axonics Modulation Technologies Inc. is beefing up plans for going public. The 5-year-old company, which makes electrical stimulation devices designed to treat ...

Sales of the R20 neurostimulator have already begun in Canada, and Axonics said in this week’s announcement that it’s aiming to expand that rollout southward to the U.S. within the next few months.

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...